Teva scraps depression program for Nuvigil after latest PhIII flop

John Carroll

($ ) today announced that it will dump its for (armodafinil) the treatment failed its Phase III test in a comparison against a placebo.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS